The seroprevalence of cytomegalovirus infection in Belgium anno 2002 and 2006: a comparative analysis with hepatitis A virus seroprevalence.


Journal

Epidemiology and infection
ISSN: 1469-4409
Titre abrégé: Epidemiol Infect
Pays: England
ID NLM: 8703737

Informations de publication

Date de publication:
01 2019
Historique:
entrez: 8 5 2019
pubmed: 8 5 2019
medline: 26 3 2020
Statut: ppublish

Résumé

Cytomegalovirus (CMV) infection is endemic worldwide but its seroprevalence varies widely. The goal of this study was to estimate the age-specific seroprevalence of CMV infection in Belgium based on two cross-sectional serological datasets from 2002 and 2006. The seroprevalence was estimated relying on diagnostic test results based on cut-off values pre-specified by the manufacturers of the tests as well as relying on mixture models applied to continuous pathogen-specific immunoglobulin G antibody titre concentrations. The age-specific seroprevalence of hepatitis A virus (HAV), based on three Belgian cross-sectional serological datasets from 1993, 2002 and 2006, was used as a comparator since individuals acquire lifelong immunity upon recovery, implying an increasing seroprevalence with age. The age group weighted overall CMV seroprevalence derived from the mixture model was 32% (95% confidence interval (CI) 31-34%) in 2002 and 31% (95% CI 30-32%) in 2006. We demonstrated that CMV epidemiology differs from the immunizing infection HAV. This was the first large-scale study of CMV and HAV serial datasets in Belgium, estimating seroprevalence specified by age and birth cohort.

Identifiants

pubmed: 31063104
pii: S0950268819000487
doi: 10.1017/S0950268819000487
pmc: PMC6518518
doi:

Substances chimiques

Antibodies, Viral 0
Immunoglobulin G 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e154

Références

Math Biosci. 2000 Apr;164(2):161-82
pubmed: 10748285
Infection. 1999;27(4-5):256-8
pubmed: 10885837
Epidemiol Infect. 2001 Aug;127(1):73-85
pubmed: 11561978
Eur J Epidemiol. 2004;19(1):85-9
pubmed: 15012028
Epidemiol Infect. 2004 Dec;132(6):1129-34
pubmed: 15635971
Int J Epidemiol. 2005 Jun;34(3):600-9
pubmed: 15831565
Pediatr Infect Dis J. 2006 Feb;25(2):156-9
pubmed: 16462294
Epidemiol Infect. 2006 Dec;134(6):1303-12
pubmed: 16650326
Epidemiol Infect. 2008 Dec;136(12):1698-706
pubmed: 18294427
Bull World Health Organ. 2008 Feb;86(2):118-25
pubmed: 18297166
Expert Rev Vaccines. 2008 Jul;7(5):535-45
pubmed: 18564009
J Clin Virol. 2009 Mar;44(3):207-10
pubmed: 19179106
Epidemiol Infect. 2010 Jun;138(6):802-12
pubmed: 19765352
Am J Obstet Gynecol. 2010 Mar;202(3):297.e1-8
pubmed: 20060091
Clin Infect Dis. 2010 Jun 1;50(11):1439-47
pubmed: 20426575
Rev Med Virol. 2010 Jul;20(4):202-13
pubmed: 20564615
Epidemiol Infect. 2011 Apr;139(4):494-504
pubmed: 20587123
Biostatistics. 2011 Apr;12(2):283-302
pubmed: 20841333
Pediatr Rev. 2011 Dec;32(12):537-42
pubmed: 22135424
Epidemiol Infect. 2012 Dec;140(12):2172-81
pubmed: 22273572
PLoS Comput Biol. 2012;8(3):e1002418
pubmed: 22396639
Wkly Epidemiol Rec. 2012 Jul 13;87(28/29):261–76
pubmed: 22905367
Vaccine. 2015 Oct 13;33(42):5723-5727
pubmed: 26190091
Lancet Infect Dis. 2017 Jun;17(6):e177-e188
pubmed: 28291720
Clin Infect Dis. 2017 Aug 15;65(4):661-668
pubmed: 28605518
PLoS Comput Biol. 2017 Sep 26;13(9):e1005719
pubmed: 28949962
Rev Med Virol. 2019 May;29(3):e2034
pubmed: 30706584
Am J Epidemiol. 1971 Nov;94(5):496-507
pubmed: 4330477
Math Biosci. 1994 Nov;124(1):59-82
pubmed: 7827424
Stat Med. 1996 Jul 30;15(14):1567-73
pubmed: 8855482
Eur J Epidemiol. 1997 Apr;13(3):275-80
pubmed: 9258525

Auteurs

G S A Smit (GSA)

Department of Virology,Parasitology and Immunology, Faculty of Veterinary Medicine, Ghent University,Merelbeke,Belgium.

S Abrams (S)

Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Hasselt University,Diepenbeek,Belgium.

P Dorny (P)

Department of Virology,Parasitology and Immunology, Faculty of Veterinary Medicine, Ghent University,Merelbeke,Belgium.

N Speybroeck (N)

Institute of Health and Society (IRSS), Université catholique de Louvain,Brussels,Belgium.

B Devleesschauwer (B)

Department of Epidemiology and Public Health,sciensano,Brussels,Belgium.

V Hutse (V)

Scientific Directorate Infectious Diseases in Humans, Service of Viral Diseases, Sciensano,Brussels,Belgium.

H Jansens (H)

Department of Laboratory Medicine,Antwerp University Hospital,Edegem,Belgium.

H Theeten (H)

Centre for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute, University of Antwerp,Antwerp,Belgium.

P Beutels (P)

Centre for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute, University of Antwerp,Antwerp,Belgium.

N Hens (N)

Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Hasselt University,Diepenbeek,Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH